Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap
Aldeyra Therapeutics announces achievement of primary endpoint in Phase 3 dry eye disease trial for reproxalap, showing statistical superiority over vehicle for ocular discomfort (P=0.004).
Highlighted Terms
Related News
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap
Aldeyra Therapeutics announces achievement of primary endpoint in Phase 3 dry eye disease trial for reproxalap, showing statistical superiority over vehicle for ocular discomfort (P=0.004).